📊 LCTX Key Takeaways
Is Lineage Cell Therapeutics, Inc. (LCTX) a Good Investment?
Lineage Cell Therapeutics is a pre-revenue biotech company burning $8.1M annually with only $1.7M in revenue and $35.9M in cash, providing approximately 4.4 years of operational runway at current burn rates. While the balance sheet is debt-free with strong liquidity, the company lacks profitable operations and positive free cash flow, with fundamentals dependent entirely on successful clinical development and commercialization of its pipeline.
Fundamentals show persistent losses and flat revenue, with extremely negative operating and net margins indicating limited commercial traction. Liquidity is solid with substantial cash, high current ratio, and no debt, providing near-term runway. Without clear revenue acceleration or expense discipline, cash burn remains a key headwind.
Lineage Cell Therapeutics, Inc. Key Strengths (LCTX)
- Strong cash position of $35.9M with zero long-term debt provides operational runway and financial flexibility
- Healthy balance sheet with positive equity of $53.9M and excellent liquidity ratios (6.89x current ratio)
- Operates in high-value cell therapeutics sector with potential for transformative treatments if successful
- Strong liquidity and 5.2x current ratio
- Zero long-term debt and no interest burden
- Positive gross margin indicating potentially scalable unit economics
LCTX Stock Risks: Lineage Cell Therapeutics, Inc. Investment Risks
- Negative free cash flow of -$8.1M annually with minimal revenue generation indicates company is pre-commercialization stage with significant execution risk
- Severe operating losses (-$7.6M) and negative profitability metrics (Operating Margin: -440.2%, Net Margin: -279.0%) show no path to profitability from current operations
- Cash burn rate requires capital raises (triggering significant shareholder dilution) or clinical success within 4+ years; no revenue growth trajectory visible
- Sustained large operating and net losses
- Flat revenue growth suggests weak commercialization
- Negative free cash flow may require future capital raises/dilution
Key Metrics to Watch
- Operating cash flow trend and burn rate deceleration
- Clinical trial progress milestones and regulatory approvals
- Revenue growth from any commercialized products and pathway to profitability
- Operating cash flow (burn rate)
- Revenue growth (YoY)
Lineage Cell Therapeutics, Inc. (LCTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.89x current ratio provides a solid financial cushion.
LCTX Profit Margin, ROE & Profitability Analysis
LCTX vs Healthcare Sector: How Lineage Cell Therapeutics, Inc. Compares
How Lineage Cell Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lineage Cell Therapeutics, Inc. Stock Overvalued? LCTX Valuation Analysis 2026
Based on fundamental analysis, Lineage Cell Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lineage Cell Therapeutics, Inc. Balance Sheet: LCTX Debt, Cash & Liquidity
LCTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lineage Cell Therapeutics, Inc.'s revenue has grown significantly by 235% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.09 indicates the company is currently unprofitable.
LCTX Revenue Growth, EPS Growth & YoY Performance
LCTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.5M | -$4.1M | $-0.02 |
| Q3 2025 | $3.7M | -$3.0M | $-0.02 |
| Q2 2025 | $1.4M | -$5.8M | $-0.03 |
| Q1 2025 | $1.4M | -$4.1M | $-0.02 |
| Q3 2024 | $1.2M | -$3.0M | $-0.02 |
| Q2 2024 | $1.4M | -$5.2M | $-0.03 |
| Q1 2024 | $1.4M | -$4.4M | $-0.03 |
| Q3 2023 | $1.2M | -$6.1M | $-0.04 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lineage Cell Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
LCTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lineage Cell Therapeutics, Inc. (CIK: 0000876343)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LCTX
What is the AI rating for LCTX?
Lineage Cell Therapeutics, Inc. (LCTX) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 66% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LCTX's key strengths?
Claude: Strong cash position of $35.9M with zero long-term debt provides operational runway and financial flexibility. Healthy balance sheet with positive equity of $53.9M and excellent liquidity ratios (6.89x current ratio). ChatGPT: Strong liquidity and 5.2x current ratio. Zero long-term debt and no interest burden.
What are the risks of investing in LCTX?
Claude: Negative free cash flow of -$8.1M annually with minimal revenue generation indicates company is pre-commercialization stage with significant execution risk. Severe operating losses (-$7.6M) and negative profitability metrics (Operating Margin: -440.2%, Net Margin: -279.0%) show no path to profitability from current operations. ChatGPT: Sustained large operating and net losses. Flat revenue growth suggests weak commercialization.
What is LCTX's revenue and growth?
Lineage Cell Therapeutics, Inc. reported revenue of $1.7M.
Does LCTX pay dividends?
Lineage Cell Therapeutics, Inc. does not currently pay dividends.
Where can I find LCTX SEC filings?
Official SEC filings for Lineage Cell Therapeutics, Inc. (CIK: 0000876343) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LCTX's EPS?
Lineage Cell Therapeutics, Inc. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LCTX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Lineage Cell Therapeutics, Inc. has a C grade with 66% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LCTX stock overvalued or undervalued?
Valuation metrics for LCTX: ROE of -8.9% (sector avg: 15%), net margin of -279.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LCTX's AI grade for 2026?
Our dual AI analysis gives Lineage Cell Therapeutics, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LCTX's free cash flow?
Lineage Cell Therapeutics, Inc.'s operating cash flow is $-8.1M, with capital expenditures of $55.0K. FCF margin is -471.5%.
How does LCTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -279.0% (avg: 12%), ROE -8.9% (avg: 15%), current ratio 6.89 (avg: 2).